Source comparison
Tesamorelin Timeline Comparison
Week 1 GH levels elevated 2–3× baseline within 2 hours post-injection; pulsatile secretion restored Fasting insulin drops 8–12%; sleep quality improves; HSL begins upregulation in adipose tissue None measurable. Weight stable, waist circumference unchanged Rec
This comparison does not assign a generated winner or score.
- Week 1
- GH levels elevated 2–3× baseline within 2 hours post-injection; pulsatile secretion restored
- Fasting insulin drops 8–12%; sleep quality improves; HSL begins upregulation in adipose tissue
- None measurable. Weight stable, waist circumference unchanged
- Receptor priming phase; biochemical foundation established but no visible outcomes
- Weeks 4–8
- Sustained GH elevation during dosing windows; IGF-1 levels rise 20–30% from baseline
- Improved insulin sensitivity; lipolytic signaling active but still accumulating
- Minimal. Some users report clothing fitting slightly looser, but DEXA shows <2% VAT reduction
- Early-stage lipolysis; cumulative fat oxidation beginning but below detection threshold for most measurement tools
- Weeks 12–16
- GH secretion pattern stabilized; pituitary response consistent across doses
- Net fat oxidation exceeds intake in VAT depot; triglyceride mobilization measurable
- VAT reduction 8–12% from baseline; waist circumference drops 1–2 cm on average
- First clinically significant body composition changes; threshold where tesamorelin's efficacy becomes visible
- Week 26
- Maximal GH response reached; further gains plateau without dose escalation
- VAT reduction 15–20% from baseline; lean mass preservation or modest gains
- Visible abdominal flattening; waist circumference reduction 3–5 cm in responders
- Peak efficacy window; body composition changes align with clinical trial endpoints